We See a Way to
identify over 85% of expected fusions in low tumor content samples by targeting 1,220+ known, rare and novel gene fusions in heme malignancies
Integrated DNA Technologies | Archer™ FUSIONPlex™ Heme Solutions
Navigate the complexity of gene fusions in heme malignancy research
One workflow for clear heme insights
Reliable fusion identification for hematologic malignancy questions that matter most
Archer FUSIONPlex™ Heme Solutions are designed to detect 1,220+ known, rare, and novel gene fusions across hematologic malignancy research applications. A single-sided, anchored priming strategy requires prior knowledge of only one fusion partner, enabling identification of fusion events that may be challenging to characterize using approaches that require both fusion partners to be known in advance.
Performance testing demonstrated identification of over 85% of expected fusions in samples containing 10% fusion-positive material, supporting reliable fusion discovery even in low tumor content research samples. Strong fusion signal recovery was observed across multiple fusion types and representative cell-line models, highlighting the solution's ability to identify diverse rearrangement events.
The workflow is paired with Archer Analysis for de novo read assembly, visualization, and interpretation, while supporting customization as new biomarkers emerge.
Designed for fusion discovery, flexibility, and practical end-to-end use
- Identifies known and novel fusion partners using AMP chemistry
- Supports broad heme malignancy research with catalog and customizable panel options
- Uses a consistent library preparation workflow with integrated Archer Analysis
- Scales from focused studies to higher-throughput research projects
Speak to one of our leading life sciences experts
TTAE
TTAE
546006278
TTAE
add
Talk to an Expert
https://lifesciences.danaher.com/
https://lifesciences.danaher.com/us/en/solutions/gene-therapy/crispr-gene-mediated.html